688363 Stock Overview
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Bloomage BioTechnology Corporation Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥60.82 |
52 Week High | CN¥84.59 |
52 Week Low | CN¥44.72 |
Beta | 0.87 |
11 Month Change | -0.46% |
3 Month Change | 13.87% |
1 Year Change | -19.98% |
33 Year Change | -64.18% |
5 Year Change | -26.25% |
Change since IPO | -28.53% |
Recent News & Updates
Why Bloomage BioTechnology's (SHSE:688363) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 06After Leaping 40% Bloomage BioTechnology Corporation Limited (SHSE:688363) Shares Are Not Flying Under The Radar
Sep 30Recent updates
Why Bloomage BioTechnology's (SHSE:688363) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 06After Leaping 40% Bloomage BioTechnology Corporation Limited (SHSE:688363) Shares Are Not Flying Under The Radar
Sep 30Need To Know: Analysts Just Made A Substantial Cut To Their Bloomage BioTechnology Corporation Limited (SHSE:688363) Estimates
Aug 30Bloomage BioTechnology Corporation Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 27Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly
Jun 02Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)
May 06Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult
May 01Shareholder Returns
688363 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -6.8% | -6.3% | -4.1% |
1Y | -20.0% | -18.6% | 3.8% |
Return vs Industry: 688363 underperformed the CN Biotechs industry which returned -18.6% over the past year.
Return vs Market: 688363 underperformed the CN Market which returned 3.8% over the past year.
Price Volatility
688363 volatility | |
---|---|
688363 Average Weekly Movement | 11.0% |
Biotechs Industry Average Movement | 8.8% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688363's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688363's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 4,417 | Yan Zhao | www.bloomagebioactive.com |
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names.
Bloomage BioTechnology Corporation Limited Fundamentals Summary
688363 fundamental statistics | |
---|---|
Market cap | CN¥29.03b |
Earnings (TTM) | CN¥440.18m |
Revenue (TTM) | CN¥5.73b |
66.1x
P/E Ratio5.1x
P/S RatioIs 688363 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688363 income statement (TTM) | |
---|---|
Revenue | CN¥5.73b |
Cost of Revenue | CN¥1.53b |
Gross Profit | CN¥4.20b |
Other Expenses | CN¥3.76b |
Earnings | CN¥440.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.92 |
Gross Margin | 73.25% |
Net Profit Margin | 7.68% |
Debt/Equity Ratio | 1.8% |
How did 688363 perform over the long term?
See historical performance and comparison